Viewing Study NCT05893966


Ignite Creation Date: 2025-12-24 @ 4:25 PM
Ignite Modification Date: 2025-12-25 @ 2:19 PM
Study NCT ID: NCT05893966
Status: RECRUITING
Last Update Posted: 2025-06-29
First Post: 2023-05-30
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
Sponsor: Samsung Medical Center
Organization:

Study Overview

Official Title: Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
Status: RECRUITING
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: BOOST-HER2
Brief Summary: The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery.

The main questions it aims to answer are:

* 7-year ipsilateral breast tumor recurrence
* 7-year disease-free survival
* 7-year locoregional recurrence
* 7-year overall survival
* Adverse events of radiation therapy

Participants will be assessed by multi-dimensional methods after radiation therapy:

* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination
* Assessment for the adverse events according to CTCAE version 5.0
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: